Jump Financial LLC Acquires New Holdings in Insulet Co. (NASDAQ:PODD)

Jump Financial LLC acquired a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,506 shares of the medical instruments supplier's stock, valued at approximately $393,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet during the fourth quarter worth $36,000. SRS Capital Advisors Inc. lifted its position in Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after acquiring an additional 56 shares during the period. Friedenthal Financial purchased a new stake in Insulet during the 4th quarter valued at about $57,000. Assetmark Inc. increased its holdings in shares of Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares during the period. Finally, Blue Trust Inc. raised its stake in shares of Insulet by 117.3% in the fourth quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock worth $72,000 after purchasing an additional 149 shares during the last quarter.

Insulet Price Performance

PODD traded up $0.99 on Thursday, reaching $253.28. 117,948 shares of the company's stock were exchanged, compared to its average volume of 713,695. The stock has a market cap of $17.79 billion, a PE ratio of 43.85, a P/E/G ratio of 3.62 and a beta of 1.30. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46. The stock's fifty day moving average price is $258.37 and its 200-day moving average price is $261.95.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Sell-side analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Analyst Upgrades and Downgrades

PODD has been the topic of several research reports. Wolfe Research downgraded shares of Insulet from an "outperform" rating to a "peer perform" rating in a report on Tuesday. TD Cowen increased their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, January 3rd. Citigroup upped their price target on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a report on Friday, February 21st. Piper Sandler lifted their price objective on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group boosted their price target on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a report on Friday, February 21st. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $293.94.

Insiders Place Their Bets

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.47% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.